Lung Sarcoidosis in Etanercept Treated Rheumatoid Arthritis Patient: a Case Report and Review of the Literature

Overview

Journal Case Rep Rheumatol

Publisher Wiley

Date 2014 Aug 7

PMID 25097790

Citations 2

Authors

Supat Thongpooswan

Adriana Abrudescu

Affiliations

Soon will be listed here.

Abstract

We report a 55-year-old female with seropositive rheumatoid arthritis for 10 years who developed large mediastinal and hilar adenopathy while receiving etanercept therapy. Chest high resolution computed tomography (HRCT) showed mediastinal lymph nodes with size of 2.3 × 3.1 centimeters. Right paratracheal lymph node biopsy showed nonnecrotizing epithelioid granulomata. All infectious studies of pulmonary lymph node tissues were negative. Etanercept was discontinued. Follow-up HRCT 6 months later showed resolution of mediastinal lymph nodes. This report should increase awareness of pulmonary sarcoidosis development in patient treated with tumor necrosis factor-alpha blocking agent, etanercept.

Citing Articles

Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review.

Suzuki A, Kamio K, Takeno M, Terasaki Y, Taniuchi N, Sato J Ther Adv Respir Dis. 2023; 17:17534666231158279.

PMID: 36872912 PMC: 9989416. DOI: 10.1177/17534666231158279.

A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis.

Mengi G, Gogus F Arch Rheumatol. 2018; 32(1):67-70.

PMID: 30375550 PMC: 6190941. DOI: 10.5606/ArchRheumatol.2017.6055.

References

Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T . Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008; 6(11):1212-7. DOI: 10.1016/j.cgh.2008.05.010. View

Callejas-Rubio J, Lopez-Perez L, Ortego-Centeno N . Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2009; 4(6):1305-13. PMC: 2643111. DOI: 10.2147/tcrm.s967. View

Clementine R, Lyman J, Zakem J, Mallepalli J, Lindsey S, Quinet R . Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol. 2010; 16(6):274-9. DOI: 10.1097/RHU.0b013e3181efa190. View

Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K, Yoneda K . Development of sarcoidosis during etanercept therapy. Intern Med. 2008; 47(11):1021-5. DOI: 10.2169/internalmedicine.47.0602. View

Kudrin A, Chilvers E, Ginawi A, Hazleman B, Griffiths M, Thiru S . Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol. 2007; 34(3):648-9. View

Kanellopoulou T, Filiotou A, Kranidioti H, Dourakis S . Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature. Clin Rheumatol. 2010; 30(4):581-3. DOI: 10.1007/s10067-010-1603-3. View

Utz J, Limper A, Kalra S, Specks U, Scott J, Vuk-Pavlovic Z . Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003; 124(1):177-85. DOI: 10.1378/chest.124.1.177. View

Daien C, Monnier A, Claudepierre P, Constantin A, Eschard J, Houvenagel E . Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009; 48(8):883-6. DOI: 10.1093/rheumatology/kep046. View

Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R . Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007; 26(11):1969-71. DOI: 10.1007/s10067-007-0594-1. View

10.

Furst D . The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2009; 39(5):327-46. DOI: 10.1016/j.semarthrit.2008.10.002. View

11.

Baughman R, Drent M, Kavuru M, Judson M, Costabel U, du Bois R . Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006; 174(7):795-802. DOI: 10.1164/rccm.200603-402OC. View

12.

Gifre L, Ruiz-Esquide V, Xaubet A, Gomez-Puerta J, Hernandez M, Sanmarti R . Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol. 2010; 47(4):208-12. DOI: 10.1016/j.arbres.2010.05.011. View

13.

Wallis R, Ehlers S . Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum. 2005; 34(5 Suppl1):34-8. DOI: 10.1016/j.semarthrit.2005.01.009. View

14.

Baughman R, Lower E, Bradley D, Raymond L, Kaufman A . Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005; 128(2):1062-47. DOI: 10.1378/chest.128.2.1062. View

15.

Antoniu S . Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets. 2009; 14(1):21-9. DOI: 10.1517/14728220903449244. View

16.

Moustou A, Matekovits A, Dessinioti C, Antoniou C, Sfikakis P, Stratigos A . Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009; 61(3):486-504. DOI: 10.1016/j.jaad.2008.10.060. View